Nluc Reporter Cell Line - LA795

LA795 mouse lung adenocarcinoma cells are a cell line established in May 1979 from a spontaneous papillary lung adenocarcinoma in T739 inbred mice. LA795 cells begin to grow 24 hours after inoculation, with the first passage taking approximately 45 days. They exhibit an epithelial-like, round morphology and primarily grow adherently. Subcutaneous transplantation experiments of LA795 cells in T739, 615, and Km mice showed a 100% metastasis rate in the lungs of T739 mice. LA795 cells exhibit stable growth characteristics in vitro and retain key features of lung adenocarcinoma, making them a valuable tool for preclinical research. Their genetic stability and consistent characteristics throughout passages ensure the reliability and reproducibility of experimental results, which is crucial for validating findings in oncology and drug development.

The Nluc reporter cell line - LA795 is genetically engineered to express the highly sensitive bioluminescent reporter enzyme NanoLuc luciferase (Nluc). This modification enables real-time, non-invasive monitoring of tumor dynamics in vivo, such as tumor growth, metastasis, and response to treatment. Its applications include high-throughput drug screening, where the bioluminescent signal can be used to quantify cell viability and compound efficacy. In cancer immunotherapy research, this cell line facilitates the assessment of immune cell infiltration and the effects of immune checkpoint inhibitors. Furthermore, its use in bioluminescence imaging (BLI) allows for longitudinal tracking of tumor progression in animal models, thus reducing the need for endpoint experiments. Therefore, the Nluc reporter cell line - LA795 is a powerful tool for advancing translational cancer research and accelerating the discovery of therapeutic drugs.